摘要
COVID-19(这里专门称为全球急性呼吸系统综合症,WARS)大流行正在全球范围内蔓延。不幸的是,没有一种特定的药物能够满足抗击这种流行病的迫切需要,导致数千人死亡。宿主导向疗法 (HDT) 理论被视为重新表述传染病治疗的理想手段。但是,尚未确定基于该理论的相关药物。此前,我们意识到咖啡因是 2 型味觉受体 (TAS2R) 的配体,其在宿主防御中起着关键作用。在这里,我们收集了有关咖啡因作为免疫调节剂的数据。出乎意料的是,我们发现咖啡因可以通过作用于多个器官来对抗WARS,这可能会阻止病毒进入细胞,刺激巨噬细胞的吞噬作用,增强呼吸,抑制细胞因子风暴。因此,咖啡因的免疫保护作用可以改善冠状病毒感染患者的治疗结果。总的来说,我们报告说,咖啡因是一种 FDA 批准的、高度安全、价格低廉且可广泛使用的药物,可能是对抗 WARS 的极好 HDT。
关键词: COVID-19、2019-nCoV、SARS-CoV-2、WARS、WARS-CoV、咖啡因、细胞因子风暴、免疫调节剂、药物、TAS2R。
Current Medicinal Chemistry
Title:Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS
Volume: 28 Issue: 27
关键词: COVID-19、2019-nCoV、SARS-CoV-2、WARS、WARS-CoV、咖啡因、细胞因子风暴、免疫调节剂、药物、TAS2R。
摘要: The COVID-19 (here specifically called Worldwide Acute Respiratory Syndrome, WARS) pandemic is surging worldwide. Unfortunately, no specific drug meets the urgent need to fight this pandemic, leading to thousands of deaths. The theory of host-directed therapies (HDTs) is viewed as the ideal means to rephrase the treatment of infectious diseases. However, related drugs based on this theory have not been identified. Previously, we realized that caffeine is the ligand of type 2 taste receptors (TAS2Rs), which play a critical role in host defense. Here, we gathered data on caffeine acting as an immunomodulator. Unexpectedly, we found that caffeine can fight WARS by acting on multiple organs, which may prevent the virus from entering the cell, stimulate the phagocytosis of macrophages, enhance breathing, and inhibit the cytokine storm. Thus, the immunoprotective effects of caffeine can improve the therapeutic outcomes in patients infected with coronavirus. Collectively, we report that caffeine, an FDA-approved, highly safe, inexpensive, and widely available drug, could be an excellent HDT for battling WARS.
Export Options
About this article
Cite this article as:
Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS, Current Medicinal Chemistry 2021; 28 (27) . https://dx.doi.org/10.2174/0929867327666201103162810
DOI https://dx.doi.org/10.2174/0929867327666201103162810 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids
Infectious Disorders - Drug Targets Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry NO-NSAIDs: From Inflammatory Mediators to Clinical Readouts
Inflammation & Allergy - Drug Targets (Discontinued) Treatment of Diabetic Foot Ulcer: An Overview Strategies for Clinical Approach
Current Diabetes Reviews Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Proteinase Inhibitors: A Promising Drug Class for Treating Leishmaniasis
Current Drug Targets Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox
Current Vascular Pharmacology Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Protective Effect of Dietary Potassium against Cardiovascular Damage in Salt-Sensitive Hypertension: Possible Role of its Antioxidant Action
Current Vascular Pharmacology Patient-Controlled Analgesia
Current Drug Targets Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Analysis of Annulated Sea Snake Venom, Hydrophis Cyanocinctus, Using Liquid Chromatography and MALDI-TOF/TOF
Current Proteomics Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Infection and Hemodialysis Access: An Updated Review.
Infectious Disorders - Drug Targets Acute Kidney Injury: Turning the Tide
Current Drug Targets The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Peptidergic Regulation of Pheochromocytoma
Current Pharmacogenomics